Abstract
Introduction: The incidence of contrast-induced nephropathy (CIN) among patients who have undergone coronary angiography is about 10%-15%. According to the recent studies, copeptin might be a potential biomarker to predict the outcomes of adverse cardiac and renal events.
Objectives: This study aimed to assess the association between serum copeptin levels and CIN.
Patients and Methods: In this cross-sectional study a total of 75 candidates of percutaneous coronary intervention (PCI) or angiography were enrolled. A 12-lead ECG was recorded. The blood sample test was taken daily to identify changes in serum creatinine levels. CIN was defined as a 25% or 44 µmol/L increase in serum creatine in comparison to baseline or an increase in serum creatinine level ≥ 0.3 mg/dL (24.6 µmol/L) within 48-72 hours after contrast medium administration. IBM SPSS version 26.0 was used for all statistical analyses at a level of statistical significance of P<0.05.
Results: The 48-hour follow-ups after the procedure revealed increased blood urea nitrogen levels in 8% and increased serum creatinine levels in 5.33% of patients. There was no relation between CIN development and serum copeptin. Our result showed no statistically significant association of serum copeptin levels with serum creatinine elevation and glomerular filtration rate (GFR) changes. Although, copeptin levels at admission, as well as hyperlipidemia, were independent predictors of serum creatinine increases and GFR decrement.
Conclusion: In conclusion, the serum copeptin level could be introduced as a simple prognostic biomarker for serum creatinine elevation and GFR decrement after contrast medium administration during coronary angiography or PCI.